Quanterix Corporation Common Stock

Day range

$2.71 – $2.88

Open

$2.82

Prev close

$2.84

Volume

349.79K

Market cap

$134.31M

Shares out

47.29M

P/E

—

P/S

0.88

P/B

0.57

P/FCF

—

ROE

-51.9%

ROA

-38.5%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 22, 2026

• Executive leadershipAug 10, 2026

  On August 10, 2026, Quanterix issued a press release announcing the appointment of Jim Gute as Quanterix's Chief Commercial Officer.

• Shareholder meetingsJun 10, 2026

  At the 2026 Annual Meeting of Stockholders of Quanterix Corporation (the "Company") held on June 9, 2026 (the "Annual Meeting"), the stockholders of the Company voted on the following matters... The stockholders approved Proposal 1, Proposal 2 and Proposal 3. The stockholders did not approve Proposal 4.

• Executive leadershipJun 9, 2026

  The Employment Agreement provides for an initial annualized base salary of $475,000, a cash sign-on bonus of $200,000, and eligibility for an annual performance bonus with an annual bonus target of up to 50% of Mr. Faessler's base salary. In connection with his appointment, Mr. Faessler also will receive a long-term equity incentive award consisting of restricted stock units (RSUs) covering shares of the Company's common stock, equivalent to three-tenths of one percent (0.30%) of the shares of Common Stock outstanding on his start date.

• Executive leadershipMay 26, 2026

  On May 14, 2026, Anthony Catalano was appointed as the Chief Operating Officer of Quanterix Corporation (the "Company"). The Company entered into an employment agreement with Mr. Catalano (the "Employment Agreement") in connection with his appointment as Chief Operating Officer. The Employment Agreement provides for an initial annualized base salary of $400,000, a cash sign-on bonus of $50,000 and eligibility for an annual performance bonus with an annual bonus target of up to 50% of Mr. Catalano's base salary.

• Executive leadershipMay 12, 2026

  Vandana Sriram will be leaving Quanterix Corporation (the "Company") and will no longer serve as the Chief Financial Officer and Treasurer of the Company effective June 15, 2026. Ms. Sriram will receive severance benefits in accordance with the terms of her employment agreement with the Company, as amended, consisting of the continued payment of her base salary for 12 months, payment of an amount equal to her annual target bonus for 2026, and subsidized health benefits for 12 months.

• SIBNSI-BONE, Inc. Common Stock-0.37%

Days to cover

7.4

Short interest

5.05M

Avg volume

679.62K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight
  positiveGlobeNewswire Inc.· Sep 22, 2026
• Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
  positiveGlobeNewswire Inc.· Sep 4, 2026
• Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight
  positiveGlobeNewswire Inc.· Aug 27, 2026
• New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
  positiveBenzinga· May 23, 2025
• $HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AKYA, WTMA, PLYA, QTRX to Act Now
  neutralGlobeNewswire Inc.· Apr 28, 2025